TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

MitoSense Inc. and Uppsala University Achieve Breakthrough in Mitochondrial Preservation with Elliott Mitochondrial Center and Sallie Astor Burdine Breast Foundation

Friday, January 26, 2024

MitoSense Inc., a leading biotechnology innovator focusing on neurodegenerative diseases, has announced a significant scientific breakthrough in collaboration with Uppsala University, the Elliott Mitochondrial Center, and the Sallie Astor Burdine Breast Foundation in Baton Rouge, Louisiana, USA. This achievement revolves around mitochondrial preservation, a crucial aspect of mitochondrial transplantation therapies.

The study titled "Extracellular Vesicles from Mesenchymal Stromal Cells (imEVs) Enhance Cold Preservation of Isolated Mitochondria" introduces an innovative method for maintaining the viability of isolated mitochondria during cold storage. This technique, which involves the use of extracellular vesicles from mesenchymal stromal cells (imEVs), represents a significant advancement in mitochondrial medicine. Mitochondrial organelle transplantation (MOT™) is a novel strategy for addressing mitochondrial dysfunction in neurodegenerative conditions like injury, Parkinson's, amyotrophic lateral sclerosis (ALS), and Alzheimer's disease. However, a major challenge for its widespread application has been the absence of an effective methodology for preserving isolated mitochondria.

Karl-Henrik Grinnemo and Sergey Rodin from Uppsala University, instrumental figures in this research, have commended the study as a "milestone in mitochondrial research." They emphasize the profound impact of this breakthrough, opening up new therapeutic possibilities for diseases associated with mitochondrial dysfunction.

Van Hipp, Chairman of MitoSense, underscores the importance of collaboration in achieving this breakthrough. "The partnership with the Elliott Mitochondrial Center and the Sallie Astor Burdine Breast Foundation significantly contributed to this discovery and reflects our shared commitment to pioneering medical solutions," he stated.

MitoSense Inc. is at the forefront of developing innovative therapies for neurodegenerative diseases. Its patented MOT™ technology has shown promising outcomes in addressing mitochondrial dysfunction. Presently, this technology is under investigation in a CAMP/Vinnova-funded project aimed at tackling ischemia-reperfusion injury post-myocardial infarction.

This collaboration marks another significant stride for MitoSense Inc. and emphasizes the company's pivotal role in advancing medical science and enhancing patient care.

 

Source: prnewswire.com

patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit